angiotensinogen and Multiple-Sclerosis

angiotensinogen has been researched along with Multiple-Sclerosis* in 2 studies

Other Studies

2 other study(ies) available for angiotensinogen and Multiple-Sclerosis

ArticleYear
Two frequent polymorphisms of angiotensinogen and their association with multiple sclerosis progression rate.
    Journal of the neurological sciences, 2011, Apr-15, Volume: 303, Issue:1-2

    A total of 195 patients with multiple sclerosis (MS) and 126 controls were investigated for angiotensinogen/(-6)A/G, M235T/and angiotensin converting enzyme I/D gene polymorphisms to test their association with MS susceptibility and/or disease progression using Global Multiple Sclerosis Severity Score (MSSS). We demonstrated a significant association of M235T polymorphism with MSSS. The MM homozygotes had the lowest (3.8), heterozygotes MT higher (5.2) and homozygotes TT the highest (5.4) mean MSSS values (P=0.02). For polymorphisms (-6)A/G of ATG, only a trend was observed (P=0.06), where the homozygotes GG carried lower MSSS values than heterozygotes and homozygotes AA. No significant association with susceptibility was observed. For ACE I/D polymorphism, neither significant differences in the genotype-phenotype study nor in the case-control study were observed.

    Topics: Adult; Alleles; Angiotensinogen; Case-Control Studies; Disease Progression; Female; Genetic Predisposition to Disease; Genetic Variation; Genotype; Heterozygote; Homozygote; Humans; Male; Multiple Sclerosis; Peptidyl-Dipeptidase A; Polymorphism, Genetic; Renin-Angiotensin System

2011
Angiotensin II controls occludin function and is required for blood brain barrier maintenance: relevance to multiple sclerosis.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2007, Aug-22, Volume: 27, Issue:34

    The blood-brain barrier (BBB) restricts molecular and cellular trafficking between the blood and the CNS. Although astrocytes are known to control BBB permeability, the molecular determinants of this effect remain unknown. We show that angiotensinogen (AGT) produced and secreted by astrocytes is cleaved into angiotensin II (AngII) and acts on type 1 angiotensin receptors (AT1) expressed by BBB endothelial cells (ECs). Activation of AT1 restricts the passage of molecular tracers across human BBB-derived ECs through threonine-phosphorylation of the tight junction protein occludin and its mobilization to lipid raft membrane microdomains. We also show that AGT knock-out animals have disorganized occludin strands at the level of the BBB and a diffuse accumulation of the endogenous serum protein plasminogen in the CNS, compared with wild-type animals. Finally, we demonstrate a reduction in the number of AGT-immunopositive perivascular astrocytes in multiple sclerosis (MS) lesions, which correlates with a reduced expression of occludin similarly seen in the CNS of AGT knock-out animals. Such a reduction in astrocyte-expressed AGT and AngII is dependent, in vitro, on the proinflammatory cytokines tumor necrosis factor-alpha and interferon-gamma. Our study defines a novel physiological role for AngII in the CNS and suggests that inflammation-induced downregulation of AngII production by astrocytes is involved in BBB dysfunction in MS lesions.

    Topics: Adult; Angiotensin II; Angiotensinogen; Animals; Astrocytes; Blood-Brain Barrier; Capillary Permeability; Cells, Cultured; Cerebral Cortex; Culture Media, Conditioned; Cytokines; Endothelial Cells; Fetus; Gene Expression Regulation; Humans; Male; Membrane Microdomains; Membrane Proteins; Mice; Mice, Knockout; Middle Aged; Multiple Sclerosis; Occludin; Receptors, Angiotensin; S100 Proteins

2007